Tanruprubart

坦鲁扑拜单抗

Report date: 2026/05/20 20:02:01
First In Class

Base Information

Drug NameTanruprubart
Drug Alias NameANX-005
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionComplement C1q subcomponent inhibitors
TargetsComplement C1q subcomponent
Therapy Area/IndicationsAnemia, Hemolytic, AutoimmuneAmyotrophic Lateral SclerosisHuntington Disease +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPhilippines +[6] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAnnexon Inc
China Registration ClassN/A

Develop Information

Active CompaniesAnnexon Inc
Inactive CompaniesN/A
Active IndicationsAnemia, Hemolytic, AutoimmuneAmyotrophic Lateral SclerosisHuntington Disease +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A